PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Jones, Graeme
TI  - The AMBITION Study
DP  - 2008 Sep 01
TA  - MD Conference Express
PG  - 14--15
VI  - 8
IP  - 5
4099  - http://mdc.sagepub.com/content/8/5/14.2.short
4100  - http://mdc.sagepub.com/content/8/5/14.2.full
AB  - Although studies have shown current anti-TNF treatments to be superior to short-term methotrexate (ie, before 24 weeks), none has shown superiority at Week 24. The AMBITION study [NCT00109408] showed that after 24 weeks, tocilizumab (an anti-IL-6 receptor antibody that inhibits IL-6 signaling) monotherapy was clinically superior to methotrexate (MTX) monotherapy in patients with rheumatoid arthritis who have not failed previous MTX or biologic treatment.